US4281013A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antiatherosclerotic use of khellin and khellinin
Assignee: Pharmacia and Upjohn Co
•
Filing: 1979-02-13
•
Granted: 1981-07-28
•
Expires: 1999-02-13
Abstract
Abstract The present specification relates to the antiatherosclerotic use of khellin and related furochromones, and further provides novel antiatherogenic 6-halofurochromones.
Inventors
- 👤 Paul E. Schurr
- 👤 Charles E. Day
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 14:58
CPC Classifications
C; C07; C07D; C07D493/00; C07D493/02; C07D493/04; C07D307/00; C07D307/77; C07D307/78; C07D307/86; C07H; C07H15/00; C07H15/26
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
47 words
A method of treating or preventing serum lipid associated atherogenic hyperbetalipoproteinemia in a human suffering from or susceptible to the development of an atherosclerotic disease which comprises: administering systemically to said human an amount of khellin or khellinin effective to significantly reduce levels of atherogenic serum betalipoproteins.
Claim 2
Independent Claim
47 words
A method of treating or preventing serum lipid associated atherogenic hyperbetalipoproteinemia in a human suffering from or susceptible to the development of an atherosclerotic disease which comprises: administering systemically to said human an amount of khellin or khellinin effective to significantly reduce levels of atherogenic serum betalipoproteins.
Claim 3
Independent Claim
34 words
A method of reversing serum lipid associated atherosclerotic lesions in a human which comprises: administering systemically to said human an amount of khellin or khellinin effective to significantly reduce levels of atherogenic serum betalipoproteins.
Claim 4
Independent Claim
34 words
A method of reversing serum lipid associated atherosclerotic lesions in a human which comprises: administering systemically to said human an amount of khellin or khellinin effective to significantly reduce levels of atherogenic serum betalipoproteins.
Claim 5
Independent Claim
34 words
A method of reversing serum lipid associated atherosclerotic lesions in a human which comprises: administering systemically to said human an amount of khellin or khellinin effective to selectively enhance levels of antiatherogenic serum alphalipoproteins.
Claim 6
Independent Claim
34 words
A method of reversing serum lipid associated atherosclerotic lesions in a human which comprises: administering systemically to said human an amount of khellin or khellinin effective to selectively enhance levels of antiatherogenic serum alphalipoproteins.
Claim 7
Independent Claim
42 words
A method of treating a human suffering from or susceptible to the development of a serum lipid associated atherosclerotic disease which comprises: administering systemically to said human an amount of khellin or khellinin effective to significantly reduce levels of atherogenic serum betalipoproteins.
Claim 8
Independent Claim
42 words
A method of treating a human suffering from or susceptible to the development of a serum lipid associated atherosclerotic disease which comprises: administering systemically to said human an amount of khellin or khellinin effective to significantly reduce levels of atherogenic serum betalipoproteins.
Claim 9
Independent Claim
42 words
A method of treating a human suffering from or susceptible to the development of a serum lipid associated atherosclerotic disease which comprises: administering systemically to said human an amount of khellin or khellinin effective to selectively enhance levels of antiatherogenic serum alphalipoproteins.
Claim 10
Independent Claim
42 words
A method of treating a human suffering from or susceptible to the development of a serum lipid associated atherosclerotic disease which comprises: administering systemically to said human an amount of khellin or khellinin effective to selectively enhance levels of antiatherogenic serum alphalipoproteins.
Claim 11
Independent Claim
47 words
A method of treating or preventing serum lipid associated atherogenic hypoalphalipoproteinemia in a human suffering from or susceptible to the development of an atherosclerotic disease which comprises: administering systemically to said human an amount of khellin or khellinin effective to significantly enhance levels of antiatherogenic serum alphalipoproteins.
Claim 12
Independent Claim
47 words
A method of treating or preventing serum lipid associated atherogenic hypoalphalipoproteinemia in a human suffering from or susceptible to the development of an atherosclerotic disease which comprises: administering systemically to said human an amount of khellin or khellinin effective to significantly enhance levels of antiatherogenic serum alphalipoproteins.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-07-27 | 1985-01-26 | 1985-07-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-07-27 | 1989-01-26 | 1989-07-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-07-27 | 1993-01-26 | 1993-07-28 | $7700.00 | Window Closed / Lapsed |